Search research articles
Contact Us
Filters
Showing results (71-80 of 144) with videos related to
Page
of 15
Sort By:
JACC. Case Reports
|
July 2, 2024
Mavacamten in Right Ventricular Outflow Tract Obstruction
Jasmine K Malhi, Richard T Carrick, Chloe Duvall, et al.
Journal of the American College of Cardiology
|
March 18, 2015
COCATS 4 Task Force 8: Training in Cardiovascular Magnetic Resonance Imaging
Christopher M Kramer, W Gregory Hundley, Raymond Y Kwong, et al.
Expert Opinion on Pharmacotherapy
|
June 5, 2023
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy
Akiva Rosenzveig, Neil Garg, Shiavax J Rao, et al.
Recent Patents on Cardiovascular Drug Discovery
|
January 19, 2012
Venous thromboembolism in patients with heart failure: in-hospital and chronic use of anti-coagulants for prevention
Nasir Shariff, Abdul Aleem, Vadim Levin, et al.
The American Journal of Cardiology
|
November 7, 2024
Efficacy of Cardiac Myosin Inhibition in Patients After Septal Reduction Therapy
Aakash Bavishi, Robyn Bryde, Marybeth Soutar, et al.
Archives of Cardiovascular Diseases
|
December 2, 2017
Regional and seasonal variations in heart failure admissions and mortality in the USA
Mahek Shah, Soumya Patnaik, Brijesh Patel, et al.
Recent Patents on Cardiovascular Drug Discovery
|
August 13, 2011
Atrial fibrillation following cardiac surgery: established and emerging strategies of prevention
Nasir Shariff, Abdul Aleem, Larry E Jacobs, et al.
JACC. Advances
|
December 30, 2024
Mavacamten: Initial Insights From the Risk Evaluation and Mitigation Strategy Program
Matthew W Martinez, Dewey Seto, Michael Cheung, et al.
International Journal of Cardiology
|
October 8, 2017
The day of the week and acute heart failure admissions: Relationship with acute myocardial infarction, 30-day readmission rate and in-hospital mortality
Mahek Shah, Soumya Patnaik, Brijesh Patel, et al.
Circulation. Heart Failure
|
November 11, 2024
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program
Milind Y Desai, Dewey Seto, Michael Cheung, et al.
Page
of 15
Search research articles
Search
Showing results (71-80 of 144) with videos related to
Sort By:
Page
of 15
JACC. Case Reports
|
July 2, 2024
Mavacamten in Right Ventricular Outflow Tract Obstruction
Jasmine K Malhi, Richard T Carrick, Chloe Duvall, et al.
Journal of the American College of Cardiology
|
March 18, 2015
COCATS 4 Task Force 8: Training in Cardiovascular Magnetic Resonance Imaging
Christopher M Kramer, W Gregory Hundley, Raymond Y Kwong, et al.
Expert Opinion on Pharmacotherapy
|
June 5, 2023
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy
Akiva Rosenzveig, Neil Garg, Shiavax J Rao, et al.
Recent Patents on Cardiovascular Drug Discovery
|
January 19, 2012
Venous thromboembolism in patients with heart failure: in-hospital and chronic use of anti-coagulants for prevention
Nasir Shariff, Abdul Aleem, Vadim Levin, et al.
The American Journal of Cardiology
|
November 7, 2024
Efficacy of Cardiac Myosin Inhibition in Patients After Septal Reduction Therapy
Aakash Bavishi, Robyn Bryde, Marybeth Soutar, et al.
Archives of Cardiovascular Diseases
|
December 2, 2017
Regional and seasonal variations in heart failure admissions and mortality in the USA
Mahek Shah, Soumya Patnaik, Brijesh Patel, et al.
Recent Patents on Cardiovascular Drug Discovery
|
August 13, 2011
Atrial fibrillation following cardiac surgery: established and emerging strategies of prevention
Nasir Shariff, Abdul Aleem, Larry E Jacobs, et al.
JACC. Advances
|
December 30, 2024
Mavacamten: Initial Insights From the Risk Evaluation and Mitigation Strategy Program
Matthew W Martinez, Dewey Seto, Michael Cheung, et al.
International Journal of Cardiology
|
October 8, 2017
The day of the week and acute heart failure admissions: Relationship with acute myocardial infarction, 30-day readmission rate and in-hospital mortality
Mahek Shah, Soumya Patnaik, Brijesh Patel, et al.
Circulation. Heart Failure
|
November 11, 2024
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program
Milind Y Desai, Dewey Seto, Michael Cheung, et al.
Page
of 15